

REMARKS

This paper is responsive to the Office Action dated June 18, 2009. Claims 1 – 8, 12 – 13 and 15 – 22 are pending in the application. Claim 4 stands objected to. Claims 5, 15, 17, 21 and 22 stand rejected. Claims 1-3, 6-8, 12, 13, 16, and 18-20 are allowed.

With the present Amendment and Reply, claims 4, 5, 21, and 22 are amended. Claim 4 is amended to remove and replace the reference to claim 2 with the subject matter referred to in claim 2. Applicants amend claim 5 to place the Markush group in proper form by replacing “or” with “and.” Applicants further amend claim 5 to remove the improper comma placement in the phrase “R1 is...alkenyl, group...” Claim 21 and 22 are amended to replace the term “composition” with the term “compound.”

No new matter is presented. Favorable consideration of the present claims is earnestly solicited.

Objection to Claim 4

Claim 4 is objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should depend from other claims in the alternative only. The Examiner specifically points to the dependency on both claims 1 and 2. In reply, Applicants amend the definition of R₁₂ in claim 4 to recite the definition as set forth in claim 2 and the reference to claim 2 is removed. With the aforementioned amendment to claim 4, the reference to claim 2 is removed. Thus, Applicants believe the objection is obviated and removal of the objection is respectfully requested.

Rejection of Claims 5, 15, 17, 21 and 22 Under §112, Second Paragraph

Claims 5, 15, 17, 21 and 22 stand rejected under §112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, the Examiner notes an improper Markush group in claim 5 with respect to the phrase “perylene or fluorenyl, benzyl...” Applicants amend claim 5 to place the Markush group in proper form by replacing “or” with “and” in compliance with MPEP 2173.05(h).

Next, the Examiner notes the improper comma placement in the phrase “R1 is...alkenyl, group” as recited in claim 5. Applicants amend claim 5 to remove the aforementioned comma.

Lastly, the Examiner notes that claims 21 and 22 refer back to “compositions” in claims 5 and 6, respectively, while claims 5 and 6 actually recite “compounds.” Applicants amend claims 21-22 to recite the term “compounds.”

In view of the amendments presented herein, Applicants respectfully request withdrawal of the rejection of claims 5, 15, 17, 21 and 22 stand under §112, second paragraph.

CONCLUSION

In view of the foregoing, Applicants submit that the subject matter of all pending claims is patentable and that such claims are in condition for allowance. Reconsideration and withdrawal of all pending rejections are respectfully requested, along with the issuance of a Notice of Allowance.

Respectfully submitted,

Date: September 16, 2009
Attorney Docket: 70447

/Mark D. Jenkins, Reg. No. 59,566/
Mark D. Jenkins
Reg. No. 59,566
Attorney for Applicant
Womble Carlyle Sandridge & Rice, PLLC
Post Office Box 7037
Atlanta, Georgia 30357-0037
Telephone: (919) 484-2317
Facsimile: (919) 484-2096
Customer No.: 26158